Tigal80
2021-09-10
yes
PROCEPT BioRobotics Stock: Surgical Robots For Urology
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":883251336,"tweetId":"883251336","gmtCreate":1631247165325,"gmtModify":1631889255115,"author":{"id":3575390834397772,"idStr":"3575390834397772","authorId":3575390834397772,"authorIdStr":"3575390834397772","name":"Tigal80","avatar":"https://static.tigerbbs.com/86f76710483a16eae0642572ffa5f1be","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>yes</p></body></html>","htmlText":"<html><head></head><body><p>yes</p></body></html>","text":"yes","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/883251336","repostId":1172713798,"repostType":4,"repost":{"id":"1172713798","pubTimestamp":1631245196,"share":"https://www.laohu8.com/m/news/1172713798?lang=&edition=full","pubTime":"2021-09-10 11:39","market":"us","language":"en","title":"PROCEPT BioRobotics Stock: Surgical Robots For Urology","url":"https://stock-news.laohu8.com/highlight/detail?id=1172713798","media":"nanalyze","summary":"Breaking news this week. Elizabeth Holmes of Theranos is formulating her “bad man made me do it” def","content":"<p>Breaking news this week. Elizabeth Holmes of Theranos is formulating her “bad man made me do it” defense, and her attorneys are considering whether or not she should take the stand. Having her stare at the jury with those Manson lamps while articulating, in that truck-driver voice, why her behavior wasn’t totally psychopathic makes about as much sense as trying to invade Russia in wintertime.</p>\n<p>Theranos was able to dupe some of the world’s most sophisticated investors because early-stage investments are often nothing but exciting stories investors believe in. The only way to demonstrate product-market fit is by showing meaningful revenues, a number we’ve pegged at $10 million annually. You can avoid Theranos types by only investing in firms with meaningful revenues. Today’s company, PROCEPT BioRobotics, just broke through that threshold halfway through this year by selling the first FDA-granted robotic surgery platform for the treatment of enlarged prostates. And now, they’re going public.</p>\n<p>About PROCEPT BioRobotics Stock<img src=\"https://static.tigerbbs.com/4a3ca7fe6960f5b129738db3f1f324e9\" tg-width=\"160\" tg-height=\"48\" referrerpolicy=\"no-referrer\"></p>\n<p>We first came across PROCEPT BioRobotics around four years ago when we wrote about <b>8 Types of Robotic Surgery Being Used Today</b>. Since then, the company raised several more rounds of funding bringing their total disclosed funding to<b>$363 million</b>. In order to understand the problem they’re trying to solve, we need to discuss the basics.</p>\n<p>A Growing Problem</p>\n<p>The prostate is a small gland in the male reproductive system that produces the fluid that protects and gives nutrients to sperm. As men age, the prostate grows larger, doubling in size between the ages of 21 and 50 years, and almost doubling again in size between the ages of 50 and 80 years. As the prostate enlarges, a condition can occur called <b>b</b>enign <b>p</b>rostatic <b>h</b>yperplasia (<b>BPH</b>). This is when the prostate gland presses against the urethra, which can obstruct or restrict the flow of urine from the bladder.</p>\n<p><img src=\"https://static.tigerbbs.com/c26ffb2cde2e63af8ed606c1a993b492\" tg-width=\"750\" tg-height=\"232\" referrerpolicy=\"no-referrer\">Normal prostate vs. enlarged prostate – Credit: PROCEPT BioRobotics</p>\n<p>BPH is the most common prostate disease and impacts approximately 40 million men in the United States. Drug therapy is often the first step in actively treating mild-to-moderate symptoms of BPH, but fails in up to 30% of men within two years. It’s also the more costly treatment option. When drug therapy fails, surgery is often the next alternative with approximately 400,000 BPH surgeries performed in the United States in 2019. Most use heat-based methods to reduce the prostate with three types of surgery accounting for the majority of BHP-related surgeries:</p>\n<ul>\n <li><b>T</b>rans<b>U</b>rethral <b>R</b>esection of the <b>P</b>rostate (<b>TURP</b>) – Uses electrocautery to cut and remove prostate tissue. Used for over a century. (<i>33.75% of 2019 BPH surgeries</i>.)</li>\n <li><b>P</b>hotoselective<b>V</b>aporization of the <b>P</b>rostate (<b>PVP</b>) – A laser fiber vaporizes prostate tissue sequentially outwards. (<i>20% of 2019 BPH surgeries</i>.)</li>\n <li>Laser Enucleation of the Prostate – Uses a surgical laser to manually resect prostate tissue through the urethra. (<i>7.5% of 2019 BPH surgeries</i>.)</li>\n</ul>\n<p>All three types of surgeries have <i>high rates of irreversible complications.</i>Published studies have shown rates of erectile dysfunction as high as 14%, 20%, and 8%, ejaculatory dysfunction as high as 89%, 50%, and 77%, and incontinence as high as 2%, 2%, and 33% for TURP, PVP, and laser enucleation, respectively.</p>\n<p>If there’s a one in five chance you’ll experience erectile dysfunction after a procedure, you’d be pretty keen on an alternative. Enter AquaBeam, a platform that doesn’t use heat, and consequently, has had very low complication rates.</p>\n<p><img src=\"https://static.tigerbbs.com/b1c0d599c5be7672af782f3a081518d6\" tg-width=\"730\" tg-height=\"552\" referrerpolicy=\"no-referrer\">Credit: PROCEPT BioRoboticsAquaBeam Robotic Systems</p>\n<p>PROCEPT has developed the first and only image-guided, heat-free robotic therapy for the treatment of<b>l</b>ower<b>u</b>rinary<b>t</b>ract<b>s</b>ymptoms (<b>LUTS</b>) due to BPH. Here’s what the entire platform looks like.</p>\n<p><img src=\"https://static.tigerbbs.com/8fab8c5730daa785fcb562d2ba28a8f0\" tg-width=\"750\" tg-height=\"704\" referrerpolicy=\"no-referrer\">Credit: PROCEPT BioRobotics</p>\n<p>The AquaBeam Handpiece seen above is a wand that’s inserted in the patient’s urethra and proceeds to cut tissue off the prostate using a pressurized jet of fluid in a procedure that typically takes less than one hour. The surgeon plans the procedure beforehand using real-time imagery, and then the platform executes the procedure while the surgeon looks on.</p>\n<p><img src=\"https://static.tigerbbs.com/6fb5613598a9042fa41faf6e8a73fe25\" tg-width=\"750\" tg-height=\"622\" referrerpolicy=\"no-referrer\">The AquaBeam Conformal Planning Unit – PROCEPT BioRobotics</p>\n<p>Nine clinical studies and over 100 peer-reviewed publications. have shown how the process is safer (<i>far fewer complications</i>) while also being more effective (<i>better symptom relief</i>).</p>\n<p><b>TAM and Revenues</b></p>\n<p>The company estimates their <b>t</b>otal <b>a</b>ddressable <b>m</b>arket (<b>TAM</b>) to be around $20 billion “based on the average selling price of our single-use handpiece” which implies a $50,000 consumable cost per procedure. Below, you can see what the consumable looks like (<i>it’s the wand-looking thing</i>):</p>\n<p><img src=\"https://static.tigerbbs.com/b71f4c4cdb01faf190c1d2dc13436d34\" tg-width=\"750\" tg-height=\"500\" referrerpolicy=\"no-referrer\">The consumable element of the AquaBeam – Credit: PROCEPT BioRobotics</p>\n<p>Since they’re only using the cost of the consumable to calculate TAM, that’s a pretty promising opportunity. If their platform was only used for 10% of all BPH surgeries, that’s still a multi-billion dollar business.</p>\n<p>As of June 30, 2021, Aquablation therapy has been utilized in the treatment of more than 5,500 patients. The first six months of this year saw 82% of sales coming from the United States with around 30% of revenues coming from consumables.</p>\n<p><img src=\"https://static.tigerbbs.com/448c2a3c4f61fe50eb11f115fe2a4f91\" tg-width=\"750\" tg-height=\"364\" referrerpolicy=\"no-referrer\">Credit: PROCEPT BioRoboticsShould You Buy PROCEPT BioRobotics stock?</p>\n<p>In March 2021, Frederick Moll assumed the role of Chairman of the Board for PROCEPT. He’s the man who founded robotic surgery darling Intuitive Surgical (ISRG) which is now a $123 billion company. For him to assume that role means he sees a lot of potential in the company. Even if the company is moderately successful, they’ll make a great bolt-on acquisition for a large medical device company likeMedtronicorStrykerwho are increasingly dabbling insurgical robotics.</p>\n<p>Even without knowing the terms of the IPO, we can still figure out what a fair price for shares might be. Here’s a look at how Intuitive Surgical is priced usingour simple valuation ratio:</p>\n<ul>\n <li>Market cap / annualized revenues</li>\n <li>$123 billion / $6 billion =<b>20</b></li>\n</ul>\n<p>We won’t invest in any company with a valuation ratio over 40, so Intuitive Surgical wouldn’t be considered overvalued based on that metric. We can now look at what market cap PROCEPT BioRobotics would command using the same ratio and our upper limit:</p>\n<ul>\n <li><b>$626.72 million</b>/ 20 = $31.336 million</li>\n <li><b>$1.25 billion</b>/ 40 = $31.336 million</li>\n</ul>\n<p>Once shares begin to trade, we can then calculate market cap. If it’s more than $1.25 billion, it’s just too richly valued to find a home in our portfolio.</p>\n<p><b>Conclusion</b></p>\n<p>Knowing that Dr. Moll is the CEO’s boss helps give us the confidence that they’ll be able to navigate the complexity of bringing a sophisticated device to the medical community. Traction in the form of meaningful revenues shows that the medical community finds value in the platform. If we decide to add this pure-playrobotic surgery stocktoour own +30 tech stock portfolio, Nanalyze Premium subscribers will receive an email alert.</p>\n<p>Should the IPO go through as planned, shares of PROCEPT BioRobotics will trade under the ticker PRCT.</p>","source":"lsy1607404209868","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PROCEPT BioRobotics Stock: Surgical Robots For Urology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPROCEPT BioRobotics Stock: Surgical Robots For Urology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 11:39 GMT+8 <a href=https://www.nanalyze.com/2021/08/procept-biorobotics-stock/><strong>nanalyze</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Breaking news this week. Elizabeth Holmes of Theranos is formulating her “bad man made me do it” defense, and her attorneys are considering whether or not she should take the stand. Having her stare ...</p>\n\n<a href=\"https://www.nanalyze.com/2021/08/procept-biorobotics-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"source_url":"https://www.nanalyze.com/2021/08/procept-biorobotics-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172713798","content_text":"Breaking news this week. Elizabeth Holmes of Theranos is formulating her “bad man made me do it” defense, and her attorneys are considering whether or not she should take the stand. Having her stare at the jury with those Manson lamps while articulating, in that truck-driver voice, why her behavior wasn’t totally psychopathic makes about as much sense as trying to invade Russia in wintertime.\nTheranos was able to dupe some of the world’s most sophisticated investors because early-stage investments are often nothing but exciting stories investors believe in. The only way to demonstrate product-market fit is by showing meaningful revenues, a number we’ve pegged at $10 million annually. You can avoid Theranos types by only investing in firms with meaningful revenues. Today’s company, PROCEPT BioRobotics, just broke through that threshold halfway through this year by selling the first FDA-granted robotic surgery platform for the treatment of enlarged prostates. And now, they’re going public.\nAbout PROCEPT BioRobotics Stock\nWe first came across PROCEPT BioRobotics around four years ago when we wrote about 8 Types of Robotic Surgery Being Used Today. Since then, the company raised several more rounds of funding bringing their total disclosed funding to$363 million. In order to understand the problem they’re trying to solve, we need to discuss the basics.\nA Growing Problem\nThe prostate is a small gland in the male reproductive system that produces the fluid that protects and gives nutrients to sperm. As men age, the prostate grows larger, doubling in size between the ages of 21 and 50 years, and almost doubling again in size between the ages of 50 and 80 years. As the prostate enlarges, a condition can occur called benign prostatic hyperplasia (BPH). This is when the prostate gland presses against the urethra, which can obstruct or restrict the flow of urine from the bladder.\nNormal prostate vs. enlarged prostate – Credit: PROCEPT BioRobotics\nBPH is the most common prostate disease and impacts approximately 40 million men in the United States. Drug therapy is often the first step in actively treating mild-to-moderate symptoms of BPH, but fails in up to 30% of men within two years. It’s also the more costly treatment option. When drug therapy fails, surgery is often the next alternative with approximately 400,000 BPH surgeries performed in the United States in 2019. Most use heat-based methods to reduce the prostate with three types of surgery accounting for the majority of BHP-related surgeries:\n\nTransUrethral Resection of the Prostate (TURP) – Uses electrocautery to cut and remove prostate tissue. Used for over a century. (33.75% of 2019 BPH surgeries.)\nPhotoselectiveVaporization of the Prostate (PVP) – A laser fiber vaporizes prostate tissue sequentially outwards. (20% of 2019 BPH surgeries.)\nLaser Enucleation of the Prostate – Uses a surgical laser to manually resect prostate tissue through the urethra. (7.5% of 2019 BPH surgeries.)\n\nAll three types of surgeries have high rates of irreversible complications.Published studies have shown rates of erectile dysfunction as high as 14%, 20%, and 8%, ejaculatory dysfunction as high as 89%, 50%, and 77%, and incontinence as high as 2%, 2%, and 33% for TURP, PVP, and laser enucleation, respectively.\nIf there’s a one in five chance you’ll experience erectile dysfunction after a procedure, you’d be pretty keen on an alternative. Enter AquaBeam, a platform that doesn’t use heat, and consequently, has had very low complication rates.\nCredit: PROCEPT BioRoboticsAquaBeam Robotic Systems\nPROCEPT has developed the first and only image-guided, heat-free robotic therapy for the treatment oflowerurinarytractsymptoms (LUTS) due to BPH. Here’s what the entire platform looks like.\nCredit: PROCEPT BioRobotics\nThe AquaBeam Handpiece seen above is a wand that’s inserted in the patient’s urethra and proceeds to cut tissue off the prostate using a pressurized jet of fluid in a procedure that typically takes less than one hour. The surgeon plans the procedure beforehand using real-time imagery, and then the platform executes the procedure while the surgeon looks on.\nThe AquaBeam Conformal Planning Unit – PROCEPT BioRobotics\nNine clinical studies and over 100 peer-reviewed publications. have shown how the process is safer (far fewer complications) while also being more effective (better symptom relief).\nTAM and Revenues\nThe company estimates their total addressable market (TAM) to be around $20 billion “based on the average selling price of our single-use handpiece” which implies a $50,000 consumable cost per procedure. Below, you can see what the consumable looks like (it’s the wand-looking thing):\nThe consumable element of the AquaBeam – Credit: PROCEPT BioRobotics\nSince they’re only using the cost of the consumable to calculate TAM, that’s a pretty promising opportunity. If their platform was only used for 10% of all BPH surgeries, that’s still a multi-billion dollar business.\nAs of June 30, 2021, Aquablation therapy has been utilized in the treatment of more than 5,500 patients. The first six months of this year saw 82% of sales coming from the United States with around 30% of revenues coming from consumables.\nCredit: PROCEPT BioRoboticsShould You Buy PROCEPT BioRobotics stock?\nIn March 2021, Frederick Moll assumed the role of Chairman of the Board for PROCEPT. He’s the man who founded robotic surgery darling Intuitive Surgical (ISRG) which is now a $123 billion company. For him to assume that role means he sees a lot of potential in the company. Even if the company is moderately successful, they’ll make a great bolt-on acquisition for a large medical device company likeMedtronicorStrykerwho are increasingly dabbling insurgical robotics.\nEven without knowing the terms of the IPO, we can still figure out what a fair price for shares might be. Here’s a look at how Intuitive Surgical is priced usingour simple valuation ratio:\n\nMarket cap / annualized revenues\n$123 billion / $6 billion =20\n\nWe won’t invest in any company with a valuation ratio over 40, so Intuitive Surgical wouldn’t be considered overvalued based on that metric. We can now look at what market cap PROCEPT BioRobotics would command using the same ratio and our upper limit:\n\n$626.72 million/ 20 = $31.336 million\n$1.25 billion/ 40 = $31.336 million\n\nOnce shares begin to trade, we can then calculate market cap. If it’s more than $1.25 billion, it’s just too richly valued to find a home in our portfolio.\nConclusion\nKnowing that Dr. Moll is the CEO’s boss helps give us the confidence that they’ll be able to navigate the complexity of bringing a sophisticated device to the medical community. Traction in the form of meaningful revenues shows that the medical community finds value in the platform. If we decide to add this pure-playrobotic surgery stocktoour own +30 tech stock portfolio, Nanalyze Premium subscribers will receive an email alert.\nShould the IPO go through as planned, shares of PROCEPT BioRobotics will trade under the ticker PRCT.","news_type":1},"isVote":1,"tweetType":1,"viewCount":148,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/883251336"}
精彩评论